Kyverna to Showcase CAR T-Cell Therapy Data for Rare Neurological Diseases at AAN 2026

Event summary

  • Kyverna Therapeutics will present new data from its neuroimmunology franchise at the AAN 2026 Annual Meeting, including a late-breaking oral presentation on the KYSA-8 registrational trial for stiff person syndrome (SPS).
  • The company will also present updated Phase 2 data for its KYSA-6 trial in generalized myasthenia gravis (gMG).
  • Kyverna's miv-cel (KYV-101) is a fully human, autologous, CD19-targeting CAR T-cell therapy designed for B-cell-driven autoimmune diseases.
  • The AAN 2026 Annual Meeting will take place from April 18-22, 2026, in Chicago, IL.

The big picture

Kyverna's presentation at AAN 2026 underscores the growing interest in CAR T-cell therapies for autoimmune diseases, moving beyond oncology. The company's focus on rare neurological conditions like SPS and gMG highlights the unmet medical needs in these areas. The success of miv-cel could redefine treatment paradigms, potentially offering durable, drug-free remission with a single dose. This strategic shift towards neuroimmunology positions Kyverna at the forefront of a burgeoning sector within the biopharmaceutical industry.

What we're watching

Clinical Efficacy
How the primary analysis from the SPS registrational trial will impact the potential approval of miv-cel for this rare disease.
Market Potential
Whether the updated Phase 2 data for gMG will position Kyverna as a leader in treating autoimmune neuromuscular diseases.
Regulatory Pathway
The pace at which Kyverna can advance its Phase 3 trial design for gMG, given the current data.